Back to Agenda
Burden of risk minimisation
Session Chair(s)
Jan Petracek, MD, MSc
CEO
Ivigee, Czech Republic
Although the analysis has been suggested by CIOMS IX and mandated by EU GVP Module XVI, no methodology has been described in the regulatory guidelines yet. Regulatory practice is evolving, and the inclusion of the Burden Analysis is not consistent across the industry. The session will explore published literature in this respect and share couple of practical hints from the real life cases.
Speaker(s)
Michael Forstner, PhD, MPH, MSc
Mesa Laubela-Consulting, Switzerland
Managing Director, Head of Pharmacoepidemiology Practice
Burden of Risk Minimisation
Jan Petracek, MD, MSc
Ivigee, Czech Republic
CEO
Have an account?